Tofanib 5mg
Tofacitinib, which is present in Tofanib 5mg Tablet, blocks the Janus kinase enzyme, reducing inflammation and the signs and symptoms of rheumatoid and psoriatic arthritis.
Description
• Rheumatoid Arthritis: Tofacitinib / Tofacitinib XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). • Psoriatic Arthritis: Tofacitinib / Tofacitinib XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). • Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). Limitations of Use: Use of Tofacitinib / Tofacitinib XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
Side effects of Tofacitinib :
>10% Overall infections (20-22%) 1-10% URTI (4.5%), Headache (4.3%), Diarrhea (4%), Nasopharyngitis (3.8%), UTI (2%), Hypertension (1.6%) <1% ANC <500/mm³ (0.07%), Lymphocytes <500/mm³ (0.04%) Frequency Not Defined Serious infections: 1.7 events per 100 patient-years Malignancies: 0.3 events per 100 patient-years
Reviews
There are no reviews yet.